The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Orthofix International's revenues will drop -26.0% and EPS will drop 0.0%.
The average estimate for revenue is $112.1 million. On the bottom line, the average EPS estimate is $0.80.
Last quarter, Orthofix International tallied revenue of $114.8 million. GAAP reported sales were 2.2% lower than the prior-year quarter's $117.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.76. GAAP EPS of $0.39 for Q3 were 41% lower than the prior-year quarter's $0.66 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 80.5%, 80 basis points better than the prior-year quarter. Operating margin was 19.0%, 110 basis points worse than the prior-year quarter. Net margin was 6.6%, 400 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $474.7 million. The average EPS estimate is $3.04.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 117 members out of 125 rating the stock outperform, and eight members rating it underperform. Among 40 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 39 give Orthofix International a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Orthofix International is outperform, with an average price target of $47.33.
Is Orthofix International the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Orthofix International to My Watchlist.